HHS says estrogen patch production doubled, but some patients still can’t fill prescriptions
Dorothy Fink said estrogen patch production doubled over the past year, but some patients still struggle to fill prescriptions.
LAS VEGAS — Manufacturers of estrogen patches doubled production over the past year, but some women still leave pharmacies without their prescriptions, National Institutes of Health official Dr. Dorothy Fink said Monday at HLTH. She said the Food and Drug Administration has expedited requests from six manufacturers as demand for menopausal hormone therapy rises.
Fink, deputy director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, spoke with Chris Klomp, chief counselor at the U.S. Department of Health and Human Services, in a Revv Stage discussion moderated by 51& founder and CEO Jodi Neuhauser. Neuhauser pressed Fink on how the government was working with manufacturers to get patches into patients’ hands.
New labels and a supply squeeze
Fink said some patients had declined to fill vaginal estrogen prescriptions after reading the older boxed warnings. She said manufacturers had stepped up production, while acknowledging that some patients were still “not getting their estrogen patch.”
The FDA approved changes for six products in February, removing statements about cardiovascular disease, breast cancer and probable dementia from their boxed warnings. The HHS Office on Women’s Health says labeling still discusses certain risks elsewhere, and the boxed warning about endometrial cancer remains on systemic estrogen-only products.
Klomp said the label changes illustrated how much work follows a scientific finding. He said “all four of those have to happen,” referring to regulatory review, commercialization, research and reimbursement.
In a September update, the FDA said it was working with all six manufacturers after hearing that patients could not readily obtain their usual patches. The measures it described went beyond adding shifts. Manufacturers were increasing batch sizes, installing equipment, adding production lines and prioritizing certain products. Those steps take place upstream of the individual pharmacy, where availability can depend on the particular product and strength a patient has been prescribed.
Fink’s account gave the audience a way to distinguish the FDA’s supply work from its labeling work. The agency first asked manufacturers to revise warnings in November 2025, then approved the first six changes in February 2026. In early November, HHS announced changes for three more products and separately described its efforts to expedite manufacturing changes. The supply effort continued even as new labeling cleared review.
One pharmacy may be out of a particular patch even when a manufacturer is making more of the drug. A November report cited an industry analysis showing that the number of patch prescriptions doubled between January 2025 and June 2026. Fink reported growth in production over a different period, so those figures are best read as evidence that both supply and demand were rising rather than as a measure of how much unmet demand remained.
The discussion covered two different uses of estrogen. A transdermal patch delivers systemic therapy. Fink separately raised the use of vaginal estrogen for recurrent urinary tract infections, a distinction that affects which product and labeling a patient and clinician review. A 2025 guideline recommends vaginal estrogen to reduce future recurrences for perimenopausal and postmenopausal women with recurrent uncomplicated UTIs when there is no contraindication.
Fink said the FDA has also approved a generic patch, a generic vaginal estrogen and other options for menopause symptoms. Those approvals broaden the list of products clinicians and patients can consider. A pharmacy’s ability to fill a particular prescription still depends on what its wholesaler can supply and whether a suitable alternative fits the patient’s treatment plan.
Klomp put the patch discussion alongside the problem of what patients pay for fertility drugs. He used a negotiated price reduction for a commonly used fertility medicine to describe the administration’s approach, which he said involved manufacturers and other countries. Neuhauser brought the comparison back to patients paying out of pocket, drawing on her experience getting a fertility prescription in South Africa. The examples involved different markets and different barriers, but both showed why the panel returned to what a patient can obtain at the pharmacy.
Fink also cautioned against confining the conversation about women’s hormones to menopause. She argued for recognizing symptoms earlier in life, using painful periods that may point to endometriosis as an example. By the end of the session, her stated measure of progress went beyond the number of products approved or grants awarded. She wanted shorter waits for diagnosis and a clearer measure of whether changes in practice improved outcomes.
Measuring what reaches patients
The speakers also discussed the October executive order directing HHS to establish a Women’s Health Division within NIH. Fink said one aim for the next two years was “decreased time to diagnosis,” with better diagnostics to help achieve it.
Neuhauser asked how HHS would extend the work of its Perinatal Improvement Collaborative. Fink pointed to improvements reported by participating hospitals and said she wanted the program to judge progress by maternal and neonatal outcomes alongside measures of how many people it served.
Fink cited a 41.5% decrease in mortality during the delivery visit among participating hospitals, compared with a 5.9% decrease at similar hospitals. She also reported a 20% reduction in severe neonatal complications in data covering more than 2.8 million births. The mortality measure was specific to the delivery encounter. The CDC’s national measure covers qualifying deaths during pregnancy and up to 42 days after a pregnancy ends.
The HHS initiative began with a contract to improve the timeliness of maternal health data and recruit a hospital network to put evidence-based maternity practices into use. At HLTH, Fink described the lack of timely data as a reason to create the collaborative in the first place. Her remarks gave participants a headline comparison, while leaving details such as the baseline event counts and adjustment methods to the underlying analysis.
Neuhauser drew a connection between that measurement work and the fertility industry, where she said the next step was to bring data together. She also closed the discussion by asking industry participants to share reimbursement obstacles they encounter when developing women’s health products. Her questions pressed the two officials on what has to happen between a federal decision and a change patients can experience.
HHS has announced a partnership with nonprofit Heartland Forward to help expand the collaborative. Klomp asked how the approach could “scale that across the whole country,” putting the next test on whether hospitals beyond the existing network can adopt and measure the same practices.